Credit Suisse’s Avita Medical RCEL Stock Holding History

Credit Suisse’s Portfolio RCEL Stock Details RCEL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-13	Closed	–	–	4238
2022 Q2	$0	Buy	+13	New	+$80	﹤0.01%	4236
2020 Q2	–	Sell	-3,960	Closed	-$123K	–	4108
2020 Q1	$123K	Buy	3,960 +629	+19%	+$26K	﹤0.01%	3781
2019 Q4	$152K	Buy	+3,331	New	+$138K	﹤0.01%	4032

Other funds holding RCEL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PVI

Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

PAMP

Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return

Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return

Credit Suisse's RCEL Position: Q3 2022 in Review

Credit Suisse sold out of Avita Medical (RCEL) in Q3 2022, closing a stake of 13 shares.

Credit Suisse first reported a position in RCEL in Q4 2019 and held it in 3 quarters. The position peaked at $152K in Q4 2019. 48 funds tracked by Wall St. Rank hold RCEL as of Q3 2022.

Credit Suisse reported no remaining Avita Medical position as of Q3 2022 after selling out during the quarter.
Credit Suisse sold 13 Avita Medical shares in Q3 2022.
Credit Suisse first reported a position in Avita Medical in Q4 2019 and held it in 3 quarters.
Credit Suisse's Avita Medical position peaked at $152K in Q4 2019.
48 funds tracked by Wall St. Rank held Avita Medical as of Q3 2022.

Based on Credit Suisse's 13F filing for Q3 2022, filed 10 Nov 2022.